Zobrazeno 1 - 10
of 43
pro vyhledávání: '"R Gadhok"'
Publikováno v:
Journal of Crohn's and Colitis. 17:i61-i62
Background Hyper-inflammatory monocyte-derived cells accumulate in the intestine and contribute to pathology in inflammatory bowel disease (IBD). Our previous work has shown that intestinal monocyte-derived cells from Crohn's Disease patients have a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Omer F. Ahmad, R Gadhok, Samantha Baillie, Hannah Gordon, Gregory Sebepos-Rogers, James O. Lindsay, Saniath Akbar, Emma Michael, Jane E Abbott, Ben Cooper
Publikováno v:
Digestive Diseases and Sciences. 65:1790-1799
Patients with inflammatory bowel disease are currently managed with the assumption that trial data are applicable to all ethnic groups. Previous studies demonstrate differences in disease severity and phenotype of Asian patients with Crohn’s diseas
Autor:
Simon G. Anderson, R Gadhok, Mark A Samaan, Sailish Honap, Gareth Parkes, Peter M. Irving, Natasha Burgess, Joel Mawdsley, James O. Lindsay, Jeremy D. Sanderson, Shuvra Ray, A Ibarra, Klaartje Kok
Publikováno v:
Posters.
Introduction Ustekinumab (UST) is effective at inducing and maintaining remission of Crohn’s disease (CD). However, real-world practice varies regarding concomitant immunomodulator (IM) use and dosing regimens, with scarce data on factors predictin
Autor:
Polychronis Pavlidis, Jonathan Segal, Omer F. Ahmad, Robin J. Dart, Homira Ayubi, Jennie Clough, Samuel Pannick, R Gadhok, Penelope Sellers, Gareth Parkes
Publikováno v:
Ahmad, O F, Ayubi, H, Clough, J, Dart, R, Gadhok, R, Pannick, S, Parkes, G, Pavlidis, P, Segal, J & Sellers, P 2021, ' Quality of care in adult patients with inflammatory bowel disease transferring between healthcare providers: multicentre audit ', Frontline Gastroenterology, vol. 12, no. 1, pp. 5-10 . https://doi.org/10.1136/flgastro-2019-101347
BackgroundInflammatory bowel disease (IBD) predominantly affects young adults at critical socioeconomic periods of their lives. There are no studies examining the process of transfer of care for adult patients with IBD changing healthcare providers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d58696434352e584712bc4be331487
https://kclpure.kcl.ac.uk/ws/files/123476217/Quality_of_care_in_AHMAD_Acc27Nov2019Epub20Jan2.pdf
https://kclpure.kcl.ac.uk/ws/files/123476217/Quality_of_care_in_AHMAD_Acc27Nov2019Epub20Jan2.pdf
Publikováno v:
Journal of Crohn's and Colitis. 16:i523-i523
Background The landmark UNITI trials 1 of Ustekinumab (UST, an anti-p40IL12/23 mAb) in treating Crohn’s disease (CD) demonstrated 6-week clinical response and 44-week clinical remission rates of 38% and 41% in TNF experienced and 52% and 62.5% in T
Autor:
R Gadhok, A Minicozzi, Hannah Gordon, B Pan-Castillo, Andrew Silver, James O. Lindsay, G Berti, J Chinaleong, Amy Lewis, Carla Felice, Roger Feakins
Publikováno v:
Journal of Crohn's and Colitis. 15:S062-S062
Background Histone-deacetylase (HDAC) enzymes are a broad class of ubiquitously expressed enzymes that modulate histone acetylation, chromatin accessibility and gene expression. In models of Inflammatory bowel disease (IBD), HDAC inhibitors, such as
Autor:
Gareth Parkes, Peter M. Irving, Edward Seward, A Ibarra, Sara McCartney, Konstantinos C. Fragkos, Roser Vega, L Whiteley, R Gadhok, Shameer Mehta, J Hassan, Farooq Rahman, Stuart Bloom, Klaartje Kok, Sailish Honap, N Burgess, James O. Lindsay
Publikováno v:
Journal of Crohn's and Colitis. 14:S439-S440
Background Ustekinumab is effective at inducing and maintaining remission of Crohn’s disease (CD) in clinical trials. However real-world practice may vary regarding use of concomitant immunomodulator (IM), dosing schedule and patient selection. We
Autor:
K Kok, Sara McCartney, Hee La Lee, Rohit Rao, R Gadhok, Ana Ibarra, L Whitley, Jonathan Evans
Publikováno v:
Abstracts of Distinction.
Introduction There is an increasing incidence of CD in adolescents and young persons (AYP). Whilst anti-TNF use in AYP is well established, little is reported on the efficacy and safety of vedolizumab. We describe our multicentre experience. Methods